8:00 am Morning Coffee & Registration
8:50 am Chair’s Opening Remarks
Exploring Advancements in Novel Conjugates with New Molecule Design & Technologies
9:00 am Targeting Sortilin (SORT1) to Unlock the Potential of Peptide Drug Conjugates (PDCs) in Oncology: Rapid Internalization and Improved Tumor Penetration Within Minutes
Synopsis
- Understand the rationale for targeting the SORT1 receptor in cancer
- Discuss the preclinical as well as the emerging clinical data of sudocetaxel zendusortide (TH1902), the lead PDC from Theratechnologies’ SORT1+ Technology™ platform
- Discuss the unique multimodal MOA of this PDC
- Explore the potential of SORT1+ Technology™ for future developments, such as novel PDC’s and combinations
9:30 am Our History to Serve the Innovators: A Step Ahead Against the Challenges of Bioconjugate
Synopsis
- Exploring a sustainable business model
- Discussing expertise, technology and integration of services
- Examining capacity shortage challenges: what it means going forward?
10:00 am A Reliable & Flexible Technology for the Rapid Conjugation of Antibodies & Other Biologics
Synopsis
- Describing how Singzyme provides a one-stop solution for antibodies and nanobodies engineering and conjugation
- Exploring how Singzyme’s technology accelerates the development of cancer immunotherapy, allowing faster production of antibody-drug-conjugates with minimal footprint on the final product and the possibility to attach two payloads with a defined DAR
- Exploring Singzyme’s technology which allows imaging for disease diagnosis: production of radiopharmaceuticals for PET scan
- imaging (Nanobodies or mAbs) with minimal radioactive waste thanks to the highest conjugation efficiency on the market
10:30 am Morning Refreshments & Speed Networking
Synopsis
This session is the ideal opportunity to have face-to-face interactions with the brightest minds working in the ADC target selection field and form meaningful business relationships.
Discovery Stream
Synopsis
Chair: Lara McGrath, Director, Translational Medicine, AstraZeneca
Leveraging Novel Platforms for Increased Efficacy
11:30 am Panel Discussion: Exploring Immune Stimulating ADCs: Opportunities & Challenges
Synopsis
- Discovering immune stimulating payloads for ADC development
- Exploring challenges in toxicity
- Drawing comparisons from alternative conjugate mechanisms of action; why immune stimulating?
12:00 pm Leveraging a Bi-specific XDC Technology Platform & its Applications for the Next-Generation of ADCs
Synopsis
- Exploring the design of the Coherent Biopharma Bi-specific XDC (Bi-XDC) platform
- Describing the evolution of Bi-XDC technology and future development
- Applications of Bi-XDC in oncology and areas for application beyond oncology indications
12:30 pm Beyond Linkers: Envisioning the Uniform PEG Technology as an Integrated Chemistry Design Platform for the Next Tiers of Next-Gen Conjugates
Synopsis
- Describe the design “power of one” in building uniform PEG infrastructures for modulating PK and PD of Next-Gen conjugates
- Interpolating from key published examples using uniform PEGs (dPEG®s)
- Examples of uniform PEG control constructs for predicting key conjugate performance functions
Development Stream
Synopsis
Chair: Marc Damelin, Vice President Biology, Mersana Therapeutics
Overcoming Hurdles in Novel Conjugate Development
11:30 am Learning from Vast Traditional ADC Data sets to Apply to the Development of Next-Generation Conjugates & Mersana’s Next-Generation Progression
Synopsis
- Exploring the development of traditional ADCs and what lessons we can take
- Touching on Mersana’s development of a novel conjugate
- Delving into how these lessons can be applied to the future of conjugates
12:00 pm Developing Next-Generation Targeted High-Capacity Drug Conjugates for Higher Drug-to-Antibody Ratio
Synopsis
- Delivering more payload beyond traditional ADCs and other high DAR platforms
- Advancing the platform of high-DAR pipeline products with a broad therapeutic index
- Platform flexibility to efficiently mix-and-match payloads and targets for fast product development
13:00 pm Lunch
Discovery Stream
Diversifying Novel Technologies to Expand the Scope of Conjugate Technologies
2:00 pm Linker Matters: Highly Stable & Efficient ADCs Utilizing Novel Native Antibodies & Peptide Linker Technology to Improve PK Exposure, Therapeutic Efficacy & Tolerability
Synopsis
- A novel peptide linker technology for site-specific payload conjugation will be introduced that enables the generation of antibody-drug conjugates (ADCs) from native antibodies in one step
- Resulting ADCs show antibody-like PK exposure with excellent activity and tolerability
- Topoisomerase-1 inhibitor ADCs were generated showing superior efficacy vs. trastuzumab deruxtecan in several animal models, highlighting the potential of this innovative peptide linker technology in enhancing the therapeutic efficacy and tolerability of ADCs
2:30 pm Exploring Novel Recombinant Human Alpha- Fetoprotein Conjugate for Effective & Safe Targeting of Cancers & Myeloid-Derived Suppressor Cells
Synopsis
- Delving into the use of novel, highly effective and safe protein-drug conjugates
- Describing how the AFP receptor is a unique target present exclusively on cancer and MDSC cells
- Highlighting how natural human proteins have been shownto be exceptionally safe in clinical trials and can be used to target AFP receptors
Development Stream
Nailing PK: Ensuring Optimal PK/PD Modeling for Novel Formats for More Successful Clinical Delivery & Dosage
2:00 pm Advancing PK/PD Modelling to Predict Dosage for Bispecific & Multispecific Antibody Drug Conjugates
Synopsis
- Identifying challenges in current PK models for bispecific and multispecific antibodies
- Developing advanced mechanistic PK/PD models for improved translation into the clinic
- Informing dosage strategy using improved PK/PD data for multi and bispecific antibodies
2:30 pm Overcoming Delivery & PK Challenges for siRNAs With Next-Generation Conjugation Techniques
Synopsis
- Discovering unfavourable characteristics of siRNAs: stability and PK challenges
- Achieving more successful delivery of siRNAs using conjugation to monoclonal antibodies
- Exploring the future of siRNAs as a payload for next generation conjugates
3:00 pm Afternoon Refreshments & Poster Session
Synopsis
The scientific poster session will serve as the perfect opportunity to showcase your recent work to your peers and allow you to learn and share insights in a relaxed atmosphere.
Highlighting Recent Clinical Data Success Stories: How is the Next-Generation Conjugate Field Progressing & What Have We Learned?
4:00 pm Exploring the Design & Preclinical Activity of AZD9592: a Bispecific EGFRMET Targeted ADC
Synopsis
- Characterization of internalization and cytotoxic properties of AZD9592, a bispecific ADC designed to selectively bind EGFR and c-MET on tumor cells and deliver a topoisomerase 1 inhibitor payload
- Using in vivo PDX studies to explore relationship of target expression to tumor growth inhibition
- Pharmacodynamic biomarkers supporting multi-faceted mechanism of action
4:30 pm Affilins® – a novel, best-in-class targeting platform
Synopsis
- Unprecedented modularity for fast innovation cycles
- Bi- and multi-specifics without limits
4:45 pm Determining Dose & Schedule for Small Molecules & Antibody Drug Conjugates in Phase I Oncology Clinical Trials
Synopsis
- Optimal biological and effective dose finding guidance for clinical development
- Preclinical modelling for human dose prediction for solid tumors
- Opportunity in hematological malignancies to measure receptor occupancy for dose selection
5:15 pm Expanding the Scope of Established Platform Technologies to Adapt to Next Generation Conjugates
Synopsis
- Novel conjugates necessitate novel solutions to develop scalable processes and reliable analytical methods in order to bring these therapeutics to the clinic, but reinventing the wheel each time is impractical.
- Leveraging a combination of literature research and development experience, we have augmented our traditional ADC platforms to accommodate efficient development and manufacturing of next generation conjugates.
- This talk will cover some of these challenges and platform retrofitting solutions